Fecal Colonization with Extended-spectrum Beta-lactamase-Producing Enterobacteriaceae and Risk Factors among Healthy Individuals: A Systematic Review and Metaanalysis

Clinical Infectious Diseases

Volumn 63, Issue 3, 2016, Pages 310-318

  Karanika, Styliani ^a   Karantanos, Theodoros ^b   Arvanitis, Marios ^b   Grigoras, Christos ^a   Mylonakis, Eleftherios ^a  

^a BROWN UNIVERSITY   (United States)

^b BOSTON MEDICAL CENTER   (United States)

Author keywords

community; ESBL fecal colonization; healthy population; metaanalysis; risk factors

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; BETA LACTAMASE CTX M; THIOL DERIVATIVE; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA-LACTAMASE CTX-2;

AFRICA; ARTICLE; ASIA; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BACTERIUM ISOLATE; CENTRAL EUROPEAN; DRUG USE; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FECAL COLONIZATION; GROUPS BY AGE; HUMAN; INFECTION CONTROL; META ANALYSIS; NORTHERN EUROPEAN; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SOUTHERN EUROPE; SYSTEMATIC REVIEW; WESTERN HEMISPHERE; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; ENZYMOLOGY; EUROPE; FECES; METABOLISM; MICROBIOLOGY; TRAVEL;

AFRICA; ANTI-BACTERIAL AGENTS; ASIA; BETA-LACTAMASES; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; EUROPE; FECES; HUMANS; PREVALENCE; TRAVEL;

EID: 84981214808     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw283     Document Type: Article

References (40)

1. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
2. National Nosocomial Infections Surveillance (NNIS). System report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
3. CDC. Antibiotic Resistance Threats in the United States. Available at: http://www. cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed 19 August 2015.
4. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56:52-9.
5. Kim BN, Woo JH, Kim MN, Ryu J, Kim YS. Clinical implications of extendedspectrum beta-lactamase-producing Klebsiella pneumoniae bacteraemia. J Hosp Infect 2002; 52:99-106.
6. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwartz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase- producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50:1257-62.
7. Ariffin H, Navaratnam P, Mohamed M, et al. Ceftazidime-resistant Klebsiella pneumoniae bloodstream infection in children with febrile neutropenia. Int J Infect Dis 2000; 4:21-5.
8. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008; 8:159-66.
9. Van Boeckel TP, Gandra S, Ashok A, et al. Global antibiotic consumption 2000 to 2010: an analysis of national pharmaceutical sales data. Lancet Infect Dis 2014; 14:742-50.
10. de Champs C, Sirot D, Chanal C, Poupart MC, Dumas MP, Sirot J. Concomitant dissemination of three extended-spectrum beta-lactamases among different Enterobacteriaceae isolated in a French hospital. J Antimicrob Chemother 1991; 27:441-57.
11. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14:933-51, table of contents.
12. Ambler RP. The structure of beta-lactamases. Philos Trans R Soc Lond B Biol Sci 1980; 289:321-31.
13. Tschudin-Sutter S, Frei R, Dangel M, Stranden A, Widmer AF. Rate of transmission of extended-spectrum beta-lactamase-producing Enterobacteriaceae without contact isolation. Clin Infect Dis 2012; 55:1505-11.
14. Gales AC, Castanheira M, Jones RN, Sader HS. Antimicrobial resistance among gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010). Diagn Microbiol Infect Dis 2012; 73:354-60.
15. D'Andrea MM, Arena F, Pallecchi L, Rossolini GM. CTX-M-type beta-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol 2013; 303:305-17.
16. Rodriguez-Bano J, Navarro MD, Romero L, et al. Risk-factors for emerging bloodstream infections caused by extended-spectrum (beta)-lactamase-producing Escherichia coli. Clin Microbiol Infect 2008; 14:180-3.
17. Cantón R, González-Alba J, Galán JC. CTX-M enzymes: origin and diffusion. Front Microbiol 2012; 3:110.
18. Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum beta-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev 2013; 26:744-58.
19. Bert F, Larroque B, Paugam-Burtz C, et al. Pretransplant fecal carriage of extended- spectrum beta-lactamase-producing Enterobacteriaceae and infection after liver transplant, France. Emerg Infect Dis 2012; 18:908-16.
20. Reddy P, Malczynski M, Obias A, et al. Screening for extended-spectrum beta-lactamase- producing Enterobacteriaceae among high-risk patients and rates of subsequent bacteremia. Clin Infect Dis 2007; 45:846-52.
21. Pena C, Pujol M, Ardanuy C, et al. An outbreak of hospital-acquired Klebsiella pneumoniae bacteraemia, including strains producing extended-spectrum betalactamase. J Hosp Infect 2001; 47:53-9.
22. Troche G, Joly LM, Guibert M, Zazzo JF. Detection and treatment of antibioticresistant bacterial carriage in a surgical intensive care unit: a 6-year prospective survey. Infect Control Hosp Epidemiol 2005; 26:161-5.
23. Carlet J. The gut is the epicentre of antibiotic resistance. Antimicrob Resist Infect Control 2012; 1:39.
24. Donskey CJ. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004; 39:219-26.
25. Nakayama T, Ueda S, Huong BT, et al. Wide dissemination of extended-spectrum beta-lactamase-producing Escherichia coli in community residents in the Indochinese peninsula. Infect Drug Resist 2015; 8:1-5.
26. Woerther PL, Angebault C, Lescat M, et al. Emergence and dissemination of extended-spectrum (beta)-lactamase-producing Escherichia coli in the community: lessons from the study of a remote and controlled population. J Infect Dis 2010; 202:515-23.
27. Nicolas-Chanoine MH, Gruson C, Bialek-Davenet S, et al. 10-fold increase (2006- 11) in the rate of healthy subjects with extended-spectrum beta-lactamase-producing Escherichia coli faecal carriage in a Parisian check-up centre. J Antimicrob Chemother 2013; 68:562-8.
28. Valenza G, Nickel S, Pfeifer Y, Krupa E, Lehner-Reindl V, Holler C. Prevalence of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli in healthy individuals in Bavaria, Germany. Int J Med Microbiol 2013; 303:93.
29. Machado E, Coque TM, Canton R, Sousa JC, Peixe L. Commensal Enterobacteriaceae as reservoirs of extended-spectrum beta-lactamases, integrons, and sul genes in Portugal. Front Microbiol 2013; 4:80.
30. Lonchel CM, Meex C, Gangoue-Pieboji J, et al. Proportion of extended-spectrum ss-lactamase-producing Enterobacteriaceae in community setting in Ngaoundere, Cameroon. BMC Infect Dis 2012; 12:53.
31. Geser N, Stephan R, Korczak BM, Beutin L, Hachler H. Molecular identification of extended-spectrum-beta-lactamase genes from Enterobacteriaceae isolated from healthy human carriers in Switzerland. Antimicrob Agents Chemother 2012; 56:1609-12.
32. Janvier F, Merens A, Delaune D, Soler C, Cavallo JD. Fecal carriage of third generation cephalosporins resistant Enterobacteriaceae in asymptomatic young adults: evolution between 1999 and 2009. Pathologie Biologie 2011; 59: 97-101.
33. Leflon-Guibout V, Blanco J, Amaqdouf K, Mora A, Guize L, Nicolas-Chanoine MH. Absence of CTX-M enzymes but high prevalence of clones, including clone ST131, among fecal Escherichia coli isolates from healthy subjects living in the area of Paris, France. J Clin Microbiol 2008; 46:3900-5.
34. Valverde A, Coque TM, Sanchez-Moreno MP, Rollan A, Baquero F, Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum betalactamase- producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42:4769-75.
35. Mathai D, Kumar VA, Paul B, et al. Fecal carriage rates of extended-spectrum betalactamase- producing Escherichia coli among antibiotic naive healthy human volunteers. Microb Drug Resist 2015; 21:59-64.
36. Lubbert C, Straube L, Stein C, et al. Colonization with extended-spectrum betalactamase- producing and carbapenemase-producing Enterobacteriaceae in international travelers returning to Germany. Int J Med Microbiol 2015; 305:148-56.
37. Sasaki T, Hirai I, Niki M, et al. High prevalence of CTX-M beta-lactamase-producing Enterobacteriaceae in stool specimens obtained from healthy individuals in Thailand. J Antimicrob Chemother 2010; 65:666-8.
38. Hammerum AM, Lester CH, Jakobsen L, Porsbo LJ. Faecal carriage of extendedspectrum beta-lactamase-producing and AmpC beta-lactamase-producing bacteria among Danish army recruits. Clin Microbiol Infect 2011; 17:566-8.
39. Ben Sallem R, Ben Slama K, Estepa V, et al. Prevalence and characterisation of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli isolates in healthy volunteers in Tunisia. Eur J Clin Microbiol Infect Dis 2012; 31: 1511-6.
40. Van Hoek AHAM, Schouls L, Van Santen MG, Florijn A, De Greeff SC, Van Duijkeren E. Molecular characteristics of extended-spectrum cephalosporin- resistant Enterobacteriaceae from humans in the community. PLoS ONE 2015; 10:e0129085.